<drug type="small molecule" created="2016-10-20" updated="2017-03-20">
  <drugbank-id primary="true">DB13025</drugbank-id>
  <name>Tiapride</name>
  <description>Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain.</description>
  <cas-number>51012-32-9</cas-number>
  <unii>LAH70H9JPH</unii>
  <average-mass>328.427</average-mass>
  <monoisotopic-mass>328.145677956</monoisotopic-mass>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>11520476</pubmed-id>
        <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
      </article>
      <article>
        <pubmed-id>10721880</pubmed-id>
        <citation>Dose M, Lange HW: The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry. 2000 Jan;33(1):19-27.</citation>
      </article>
      <article>
        <pubmed-id>7201401</pubmed-id>
        <citation>Bischoff S, Bittiger H, Delini-Stula A, Ortmann R: Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol. 1982 Apr 23;79(3-4):225-32.</citation>
      </article>
      <article>
        <pubmed-id>2958291</pubmed-id>
        <citation>Norman T, Chiu E, James RH, Gregory MS: Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease. Eur J Clin Pharmacol. 1987;32(6):583-6.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.</indication>
  <pharmacodynamics>Tiapride displays a relatively high regional selectivity for limbic areas. One study found that, in contrast with haloperidol, which displays equal affinity for receptors in the rat limbic system and striatum, tiapride shows over three times as much affinity for limbic areas than striatal areas.&#13;
Another study in rats found tiapride's affinity for the septum, a limbic region, to be over thirty times as high as for the striatum.&#13;
Efficacy at the D2 receptor is moderate, with 80 percent of receptors occupied even in the presence of excess tiapride concentrations.</pharmacodynamics>
  <mechanism-of-action>Tiapride is a dopamine D2 and D3 receptor antagonist. It is more selective than other neuroleptic drugs such as haloperidol and risperidone, which not only target four of the five known dopamine receptor subtypes (D1-4), but also block serotonin (5-HT2A, 2C), α1- and α2-adrenergic, and histamine H1 receptors. Compared to these drugs, tiapride has a relatively moderate affinity for its target receptors, displacing 50 percent of 3H-raclopride binding at a concentration of 320 nM at D2 receptors and a concentration of 180 nM at D3 receptors.</mechanism-of-action>
  <toxicity/>
  <metabolism>Tiapride is minimally metabolized in humans, 70 % of the drug is eliminated in unchanged form in the urine within 24 hours. Only low concentration of N-desethyl tiapride and tiapride N-oxide and no phase II metabolites were detected.</metabolism>
  <absorption>The bioavailability of tiapride is approximately 75 percent. Peak plasma concentrations are attained between 0.4 and 1.5 hours following administration, and steady-state concentrations achieved 24 to 48 hours after beginning administration 3 times a day.  Benzamide and its derivatives are highly water-soluble, and because of their polarity are believed to cross the blood–brain barrier via carrier-mediated transport. </absorption>
  <half-life>2.9–3.6 hours</half-life>
  <protein-binding>Negligible</protein-binding>
  <route-of-elimination>Urine (70% as unchanged tiapride)</route-of-elimination>
  <volume-of-distribution>Tiapride distributes rapidly and exhibits virtually no binding to plasma proteins, giving it a relatively high volume of distribution</volume-of-distribution>
  <clearance>16.6 l/h.</clearance>
  <classification>
    <description>This compound belongs to the class of chemical entities known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.</description>
    <direct-parent>Benzenesulfonyl compounds</direct-parent>
    <kingdom>Chemical entities</kingdom>
    <superclass>Organic compounds</superclass>
    <class>Benzenoids</class>
    <subclass>Benzene and substituted derivatives</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Anisoles</alternative-parent>
    <alternative-parent>Carboximidic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methoxybenzenes</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Sulfones</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzenesulfonyl group</substituent>
    <substituent>Carboximidic acid</substituent>
    <substituent>Carboximidic acid derivative</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methoxybenzene</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Sulfone</substituent>
    <substituent>Sulfonyl</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002373</drugbank-id>
      <name>Tiapride hydrochloride</name>
      <unii>25N106WEDO</unii>
      <cas-number>51012-33-0</cas-number>
      <inchikey>OTFDPNXIVHBTKW-UHFFFAOYSA-N</inchikey>
      <average-mass>364.89</average-mass>
      <monoisotopic-mass>364.1223562</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Gramalil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Italprid</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Luxoben</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Sereprile</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Tiapridal</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Antipsychotic Agents</category>
      <mesh-id>D014150</mesh-id>
    </category>
    <category>
      <category>Benzamides</category>
      <mesh-id>D001549</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Carboxylic Acids</category>
      <mesh-id>D002264</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Depressants</category>
      <mesh-id>D002492</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Dopamine Agents</category>
      <mesh-id>D015259</mesh-id>
    </category>
    <category>
      <category>Dopamine Antagonists</category>
      <mesh-id>D018492</mesh-id>
    </category>
    <category>
      <category>Ethylamines</category>
      <mesh-id>D005021</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons</category>
      <mesh-id>D006838</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Aromatic</category>
      <mesh-id>D006841</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Cyclic</category>
      <mesh-id>D006844</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Organic Chemicals</category>
      <mesh-id>D009930</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Psycholeptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychotropic Drugs</category>
      <mesh-id>D011619</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Tranquilizing Agents</category>
      <mesh-id>D014149</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes>
    <atc-code code="N05AL03">
      <level code="N05AL">Benzamides</level>
      <level code="N05A">ANTIPSYCHOTICS</level>
      <level code="N05">PSYCHOLEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>3,4-Methylenedioxyamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>3,4-Methylenedioxymethamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of adverse effects can be increased when Acepromazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>The risk or severity of adverse effects can be increased when adipiplon is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The risk or severity of adverse effects can be increased when Agomelatine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Alfentanil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of adverse effects can be increased when Almotriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Alprazolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Amobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of adverse effects can be increased when Amoxapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Amperozide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>The risk or severity of adverse effects can be increased when Articaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The risk or severity of adverse effects can be increased when Asenapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Azaperone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The risk or severity of adverse effects can be increased when Azelastine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Baclofen is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The risk or severity of adverse effects can be increased when Barbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Benperidol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01086</drugbank-id>
      <name>Benzocaine</name>
      <description>The risk or severity of adverse effects can be increased when Benzocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>The risk or severity of adverse effects can be increased when Brimonidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The risk or severity of adverse effects can be increased when Bromazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The risk or severity of adverse effects can be increased when Brotizolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The risk or severity of adverse effects can be increased when Buspirone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11502</drugbank-id>
      <name>Butacaine</name>
      <description>The risk or severity of adverse effects can be increased when Butacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The risk or severity of adverse effects can be increased when Butalbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11148</drugbank-id>
      <name>Butamben</name>
      <description>The risk or severity of adverse effects can be increased when Butamben is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butethal</name>
      <description>The risk or severity of adverse effects can be increased when Butethal is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Butorphanol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of adverse effects can be increased when Cabergoline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Carfentanil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Cetirizine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>The risk or severity of adverse effects can be increased when Chlormezanone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>Tiapride may decrease the stimulatory activities of Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>The risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of adverse effects can be increased when Clemastine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of adverse effects can be increased when Clidinium is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The risk or severity of adverse effects can be increased when Clobazam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>clomethiazole</name>
      <description>The risk or severity of adverse effects can be increased when clomethiazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of adverse effects can be increased when Clomipramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The risk or severity of adverse effects can be increased when Clonazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of adverse effects can be increased when Clonidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepate</name>
      <description>The risk or severity of adverse effects can be increased when Clorazepate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Clozapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of adverse effects can be increased when Cocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of adverse effects can be increased when Codeine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of adverse effects can be increased when Cyclizine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of adverse effects can be increased when Dantrolene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00298</drugbank-id>
      <name>Dapiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The risk or severity of adverse effects can be increased when deramciclane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Desflurane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of adverse effects can be increased when Desipramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of adverse effects can be increased when Desloratadine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of adverse effects can be increased when Detomidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of adverse effects can be increased when Dezocine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The risk or severity of adverse effects can be increased when Diazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>Tiapride may decrease the stimulatory activities of Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difenoxin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The risk or severity of adverse effects can be increased when Doramectin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of adverse effects can be increased when Doxepin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of adverse effects can be increased when DPDPE is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>The risk or severity of adverse effects can be increased when Drotebanol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of adverse effects can be increased when Duloxetine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01525</drugbank-id>
      <name>Ecgonine</name>
      <description>The risk or severity of adverse effects can be increased when Ecgonine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04688</drugbank-id>
      <name>ECGONINE METHYL ESTER</name>
      <description>The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Ecopipam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The risk or severity of adverse effects can be increased when Efavirenz is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of adverse effects can be increased when Eletriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of adverse effects can be increased when Enflurane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The risk or severity of adverse effects can be increased when Entacapone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The risk or severity of adverse effects can be increased when Ergonovine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The risk or severity of adverse effects can be increased when Ergotamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of adverse effects can be increased when Escitalopram is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The risk or severity of adverse effects can be increased when Estazolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The risk or severity of adverse effects can be increased when Ethotoin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Ethyl carbamate</name>
      <description>The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08987</drugbank-id>
      <name>Etidocaine</name>
      <description>The risk or severity of adverse effects can be increased when Etidocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>The risk or severity of adverse effects can be increased when Etifoxine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The risk or severity of adverse effects can be increased when Etizolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Etoperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of adverse effects can be increased when Etorphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of adverse effects can be increased when Ezogabine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The risk or severity of adverse effects can be increased when Felbamate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamine</name>
      <description>The risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of adverse effects can be increased when Fentanyl is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of adverse effects can be increased when Fexofenadine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Flibanserin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of adverse effects can be increased when Flunarizine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Fluoxetine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of adverse effects can be increased when Flupentixol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The risk or severity of adverse effects can be increased when Flurazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone Propionate</name>
      <description>The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The risk or severity of adverse effects can be increased when Fospropofol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Frovatriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The risk or severity of adverse effects can be increased when Gabapentin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>gabapentin enacarbil</name>
      <description>The risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>Gamma Hydroxybutyric Acid</name>
      <description>The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>The risk or severity of adverse effects can be increased when Glutethimide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of adverse effects can be increased when Guanfacine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The risk or severity of adverse effects can be increased when Halazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of adverse effects can be increased when Haloperidol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Halothane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Heroin</name>
      <description>The risk or severity of adverse effects can be increased when Heroin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09352</drugbank-id>
      <name>Hydroxyamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The risk or severity of adverse effects can be increased when Iloperidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of adverse effects can be increased when Imipramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Isoflurane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of adverse effects can be increased when Ketamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The risk or severity of adverse effects can be increased when Ketazolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Levetiracetam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Levocabastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Levocetirizine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The risk or severity of adverse effects can be increased when Levodopa is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levomethadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Levorphanol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The risk or severity of adverse effects can be increased when Lidocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Linezolid is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>Lithium may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of adverse effects can be increased when Lofentanil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The risk or severity of adverse effects can be increased when Loratadine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lorazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The risk or severity of adverse effects can be increased when Lorcaserin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Loxapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05700</drugbank-id>
      <name>Lu AA21004</name>
      <description>The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium Sulfate</name>
      <description>Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Maprotiline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The risk or severity of adverse effects can be increased when Meclizine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Medetomidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The risk or severity of adverse effects can be increased when Melatonin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of adverse effects can be increased when Melperone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>Tiapride may decrease the stimulatory activities of Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>Tiapride may decrease the stimulatory activities of Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>Tiapride may increase the arrhythmogenic activities of Mequitazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Metaxalone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of adverse effects can be increased when Methadone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Methamphetamine</name>
      <description>Tiapride may decrease the stimulatory activities of Methamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>The risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>The risk or severity of adverse effects can be increased when Methaqualone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>The risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The risk or severity of adverse effects can be increased when Methohexital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of adverse effects can be increased when Methsuximide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Tiapride may increase the sedative activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Milnacipran is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>Tiapride may decrease the stimulatory activities of MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of adverse effects can be increased when Moclobemide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Molindone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Morphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of adverse effects can be increased when Naratriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of adverse effects can be increased when Nefazodone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13116</drugbank-id>
      <name>Norflurane</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with 1,1,1,2 Tetrafluoroethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of adverse effects can be increased when Normethadone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Olopatadine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of adverse effects can be increased when Ondansetron is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of adverse effects can be increased when Opium is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Osanetant is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The risk or severity of adverse effects can be increased when Oxazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12532</drugbank-id>
      <name>Oxetacaine</name>
      <description>The risk or severity of adverse effects can be increased when Oxetacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00892</drugbank-id>
      <name>Oxybuprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of adverse effects can be increased when Oxycodone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of adverse effects can be increased when Paliperidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of adverse effects can be increased when Paroxetine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Perazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Perospirone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Perphenazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Pethidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of adverse effects can be increased when Phenelzine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11304</drugbank-id>
      <name>Phenoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>Tiapride may decrease the stimulatory activities of Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The risk or severity of adverse effects can be increased when Phenytoin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of adverse effects can be increased when Pimozide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Pipamperone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of adverse effects can be increased when Pipotiazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of adverse effects can be increased when Piritramide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The risk or severity of adverse effects can be increased when Pizotifen is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Tiapride may increase the sedative activities of Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09345</drugbank-id>
      <name>Pramocaine</name>
      <description>The risk or severity of adverse effects can be increased when Pramocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The risk or severity of adverse effects can be increased when Prazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of adverse effects can be increased when Pregabalin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Pregnanolone</name>
      <description>The risk or severity of adverse effects can be increased when Pregnanolone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00750</drugbank-id>
      <name>Prilocaine</name>
      <description>The risk or severity of adverse effects can be increased when Prilocaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The risk or severity of adverse effects can be increased when Primidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Procaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Procarbazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of adverse effects can be increased when Promazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of adverse effects can be increased when Promethazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00807</drugbank-id>
      <name>Proparacaine</name>
      <description>The risk or severity of adverse effects can be increased when Proparacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of adverse effects can be increased when Propofol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09342</drugbank-id>
      <name>Propoxycaine</name>
      <description>The risk or severity of adverse effects can be increased when Propoxycaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06671</drugbank-id>
      <name>PSD502</name>
      <description>The risk or severity of adverse effects can be increased when PSD502 is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>Tiapride may decrease the stimulatory activities of Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The risk or severity of adverse effects can be increased when Quazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of adverse effects can be increased when Quetiapine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09097</drugbank-id>
      <name>Quinagolide</name>
      <description>The therapeutic efficacy of Quinagolide can be decreased when used in combination with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Raclopride is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The risk or severity of adverse effects can be increased when Ramelteon is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of adverse effects can be increased when Rasagiline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Remifentanil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of adverse effects can be increased when Reserpine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The risk or severity of adverse effects can be increased when Risperidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of adverse effects can be increased when Ritanserin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>Tiapride may decrease the stimulatory activities of Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Rizatriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of adverse effects can be increased when Romifidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Tiapride may increase the sedative activities of Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Tiapride may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The risk or severity of adverse effects can be increased when Rufinamide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02539</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>SAGE-547</name>
      <description>The risk or severity of adverse effects can be increased when Sage 547 is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Secobarbital is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of adverse effects can be increased when Selegiline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Sertindole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of adverse effects can be increased when Sertraline is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The risk or severity of adverse effects can be increased when Stiripentol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Sumatriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>The risk or severity of adverse effects can be increased when Tandospirone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The risk or severity of adverse effects can be increased when Tasimelteon is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid Phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The risk or severity of adverse effects can be increased when Temazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09085</drugbank-id>
      <name>Tetracaine</name>
      <description>The risk or severity of adverse effects can be increased when Tetracaine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The risk or severity of adverse effects can be increased when Thiamylal is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The risk or severity of adverse effects can be increased when Thiopental is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of adverse effects can be increased when Thioridazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Thiothixene is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The risk or severity of adverse effects can be increased when Tiagabine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The risk or severity of adverse effects can be increased when Tiletamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Tolcapone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The risk or severity of adverse effects can be increased when Topiramate is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02665</drugbank-id>
      <name>Trans-2-Phenylcyclopropylamine</name>
      <description>The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of adverse effects can be increased when Trazodone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of adverse effects can be increased when Triazolam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of adverse effects can be increased when Trimipramine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of adverse effects can be increased when Triprolidine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12972</drugbank-id>
      <name>UC1010</name>
      <description>The risk or severity of adverse effects can be increased when Uc1010 is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Valproic Acid is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The risk or severity of adverse effects can be increased when Vigabatrin is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of adverse effects can be increased when Vilazodone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of adverse effects can be increased when Xylazine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The risk or severity of adverse effects can be increased when Zaleplon is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of adverse effects can be increased when Ziconotide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of adverse effects can be increased when Tiapride is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Zolazepam is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Tiapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Zonisamide is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Zopiclone is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Zotepine is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiapride.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.55</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.39e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-[2-(diethylamino)ethyl]-5-methanesulfonyl-2-methoxybenzene-1-carboximidic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tiapride</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>328.427</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>328.145677956</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C15H24N2O4S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>JTVPZMFULRWINT-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>79.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>88.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>35.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>6.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94666</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08590</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tiapride</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL84158</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000756</id>
      <name>D(2) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>blocker</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14416" source="Swiss-Prot">
    <name>D(2) dopamine receptor</name>
    <general-function>Potassium channel regulator activity</general-function>
    <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.</specific-function>
    <gene-name>DRD2</gene-name>
    <locus>11q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>38-60
71-93
109-130
152-172
189-213
374-395
410-431</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.85</theoretical-pi>
    <molecular-weight>50618.91</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3023</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M30625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>215</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>215</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14416</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Dopamine D2 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001508|D(2) dopamine receptor
MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVS
REKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTA
SILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQN
ECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPL
KGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPP
SHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSR
RKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSA
VNPIIYTTFNIEFRKAFLKILHC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021274|D(2) dopamine receptor (DRD2)
ATGGATCCACTGAATCTGTCCTGGTATGATGATGATCTGGAGAGGCAGAACTGGAGCCGG
CCCTTCAACGGGTCAGACGGGAAGGCGGACAGACCCCACTACAACTACTATGCCACACTG
CTCACCCTGCTCATCGCTGTCATCGTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC
CGCGAGAAGGCGCTGCAGACCACCACCAACTACCTGATCGTCAGCCTCGCAGTGGCCGAC
CTCCTCGTCGCCACACTGGTCATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTGAGTGG
AAATTCAGCAGGATTCACTGTGACATCTTCGTCACTCTGGACGTCATGATGTGCACGGCG
AGCATCCTGAACTTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCCATGCCCATG
CTGTACAATACGCGCTACAGCTCCAAGCGCCGGGTCACCGTCATGATCTCCATCGTCTGG
GTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC
GAGTGCATCATTGCCAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG
CCCTTCATTGTCACCCTGCTGGTCTACATCAAGATCTACATTGTCCTCCGCAGACGCCGC
AAGCGAGTCAACACCAAACGCAGCAGCCGAGCTTTCAGGGCCCACCTGAGGGCTCCACTA
AAGGGCAACTGTACTCACCCCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT
GGGAGTTTCCCAGTGAACAGGCGGAGAGTGGAGGCTGCCCGGCGAGCCCAGGAGCTGGAG
ATGGAGATGCTCTCCAGCACCAGCCCACCCGAGAGGACCCGGTACAGCCCCATCCCACCC
AGCCACCACCAGCTGACTCTCCCCGACCCGTCCCACCATGGTCTCCACAGCACTCCCGAC
AGCCCCGCCAAACCAGAGAAGAATGGGCATGCCAAAGACCACCCCAAGATTGCCAAGATC
TTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTCAAGACCATGAGCCGT
AGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTCGCCATTGTTCTCGGC
GTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGTGAC
TGCAACATCCCGCCTGTCCTGTACAGCGCCTTCACGTGGCTGGGCTATGTCAACAGCGCC
GTGAACCCCATCATCTACACCACCTTCAACATTGAGTTCCGCAAGGCCTTCCTGAAGATC
CTCCACTGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>acrosomal vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ciliary membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nonmotile primary cilium</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>postsynaptic density</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon terminus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perikaryon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sperm flagellum</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>potassium channel regulator activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cAMP metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of sodium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of heart rate</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex GABAergic interneuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>grooming behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult walking behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>pigmentation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokinesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>long-term memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synapse assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peristalsis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>associative learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>feeding behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of long-term synaptic potentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron-neuron synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to axon injury</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of circadian sleep/wake cycle, sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of urine volume</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>striatum development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to iron ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nicotine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenohypophysis development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synaptic transmission, GABAergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion involved in locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prepulse inhibition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to toxic substance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of long-term neuronal synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of smell</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glial cell-derived neurotrophic factor secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>auditory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synapse structural plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of phosphoprotein phosphatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of voltage-gated calcium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to light stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching morphogenesis of a nerve</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>temperature homeostasis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000581</id>
      <name>D(3) dopamine receptor</name>
      <organism>Human</organism>
      <actions>
        <action>blocker</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35462" source="Swiss-Prot">
    <name>D(3) dopamine receptor</name>
    <general-function>G-protein coupled amine receptor activity</general-function>
    <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.</specific-function>
    <gene-name>DRD3</gene-name>
    <locus>3q13.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>33-55
66-88
105-126
150-170
188-212
330-351
367-388</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.07</theoretical-pi>
    <molecular-weight>44224.335</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3024</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>DRD3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U32499</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>927342</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>216</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>216</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35462</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>DRD3_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Dopamine D3 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001159|D(3) dopamine receptor
MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERAL
QTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILN
LCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTV
CSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQ
QTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRK
LSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHV
SPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021269|D(3) dopamine receptor (DRD3)
ATGGCATCTCTGAGCCAGCTGAGTGGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC
ACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC
CTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG
CAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC
TTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC
ATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT
CTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT
GGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG
GCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC
TGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC
TTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG
AAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA
CAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG
GACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG
AAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA
CTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG
CCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC
TGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG
TCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT
GTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>apical part of cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled amine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dopamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of circadian sleep/wake cycle, sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokinesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cAMP metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood volume by renin-angiotensin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prepulse inhibition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion involved in locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine uptake involved in synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gastric emptying</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>musculoskeletal movement, spinal reflex action</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of oligodendrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of sodium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>social behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acid secretion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0004862</id>
      <name>Serotonin Receptors</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08908" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1A</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.</specific-function>
    <gene-name>HTR1A</gene-name>
    <locus>5q11.2-q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>37-62
74-98
111-132
153-178
192-217
346-367
379-403</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.05</theoretical-pi>
    <molecular-weight>46106.335</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5286</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M28269</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189928</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08908</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1A</synonym>
      <synonym>ADRB2RL1</synonym>
      <synonym>ADRBRL1</synonym>
      <synonym>G-21</synonym>
      <synonym>Serotonin receptor 1A</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)
ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG
ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT
CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC
ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC
ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC
AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC
ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC
CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT
TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC
CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC
TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA
GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC
CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC
AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG
GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC
TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT
TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG
AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC
TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG
TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC
GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC
CGCCAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exploration behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of serotonin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P28222" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1B</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.</specific-function>
    <gene-name>HTR1B</gene-name>
    <locus>6q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>50-75
85-110
124-145
166-187
206-228
316-336
350-371</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.82</theoretical-pi>
    <molecular-weight>43567.535</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5287</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D10995</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>219679</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28222</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1B</synonym>
      <synonym>5-HT-1D-beta</synonym>
      <synonym>HTR1DB</synonym>
      <synonym>S12</synonym>
      <synonym>Serotonin 1D beta receptor</synonym>
      <synonym>Serotonin receptor 1B</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019014|5-hydroxytryptamine receptor 1B
MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT
LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV
VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI
SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL
KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE
KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL
NSLINPIIYTMSNEDFKQAFHKLIRFKCTS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019015|5-hydroxytryptamine receptor 1B (HTR1B)
ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT
CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC
CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC
TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG
CACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATC
CTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG
GTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC
TGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA
AGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC
TCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG
GTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC
ACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG
AAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC
CCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA
TCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA
AAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG
GGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC
AAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC
AACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC
CATAAACTGATACGTTTTAAGTGCACAAGTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, GABAergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to alkaloid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to temperature stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of serotonin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drinking behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to mineralocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P28221" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1D</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.</specific-function>
    <gene-name>HTR1D</gene-name>
    <locus>1p36.3-p34.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>39-64
76-98
113-134
155-176
195-217
303-326
336-360</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.85</theoretical-pi>
    <molecular-weight>41906.38</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5289</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1D</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M89955</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>177772</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28221</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1D_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1D</synonym>
      <synonym>5-HT-1D-alpha</synonym>
      <synonym>HTR1DA</synonym>
      <synonym>HTRL</synonym>
      <synonym>Serotonin 1D alpha receptor</synonym>
      <synonym>Serotonin receptor 1D</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010458|5-hydroxytryptamine receptor 1D
MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVL
TTILLTRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDIT
CCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAK
AQEEMSDCLVNTSQISYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFT
TAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIKLADSALERKRISAARERKAT
KILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFN
EEFRQAFQKIVPFRKAS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010459|5-hydroxytryptamine receptor 1D (HTR1D)
ATGTCCCCACTGAACCAGTCAGCAGAAGGCCTTCCCCAGGAGGCCTCCAACAGATCCCTG
AATGCCACAGAAACCTCAGAGGCTTGGGATCCCAGGACCCTCCAGGCGCTCAAGATCTCC
CTTGCCGTGGTCCTTTCCGTCATCACACTGGCCACAGTCCTCTCCAATGCCTTTGTACTC
ACCACCATCTTACTCACCAGGAAGCTCCACACCCCTGCCAACTACCTGATTGGCTCCCTG
GCCACCACCGACCTCTTGGTTTCCATCTTGGTAATGCCCATCAGCATCGCCTATACCATC
ACCCACACCTGGAACTTTGGCCAAATCTTGTGTGACATCTGGCTGTCCTCTGACATCACG
TGCTGCACAGCCTCCATCCTGCATCTCTGTGTCATTGCTCTGGACAGGTACTGGGCAATC
ACAGATGCCCTGGAATACAGTAAACGCAGGACGGCTGGCCACGCGGCCACCATGATCGCC
ATTGTCTGGGCCATCTCCATCTGCATCTCCATCCCCCCGCTCTTCTGGCGGCAGGCCAAG
GCCCAGGAGGAGATGTCGGACTGTCTGGTGAACACCTCTCAGATCTCCTACACCATCTAC
TCCACCTGTGGGGCCTTCTACATTCCCTCGGTGTTGCTCATCATCCTATATGGCCGGATC
TACCGGGCTGCCCGGAACCGCATCCTGAATCCACCCTCACTCTATGGGAAGCGCTTCACC
ACGGCCCACCTCATCACAGGCTCTGCCGGGTCCTCGCTCTGCTCGCTCAACTCCAGCCTC
CATGAGGGGCACTCGCACTCGGCTGGCTCCCCTCTCTTTTTCAACCACGTGAAAATCAAG
CTTGCTGACAGTGCCCTGGAACGCAAGAGGATTTCTGCTGCTCGAGAAAGGAAAGCCACT
AAAATCCTGGGCATCATTCTGGGGGCCTTTATCATCTGCTGGCTGCCCTTCTTCGTGGTG
TCTCTGGTCCTCCCCATCTGCCGGGACTCCTGCTGGATCCACCCGGCGCTCTTTGACTTC
TTCACCTGGCTAGGCTATTTAAACTCCCTCATCAATCCAATAATCTACACTGTGTTTAAT
GAAGAGTTTCGGCAAGCTTTTCAGAAAATTGTCCCTTTCCGGAAGGCCTCCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to toxic substance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intestine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of locomotion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P28566" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1E</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.</specific-function>
    <gene-name>HTR1E</gene-name>
    <locus>6q14-q15</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>23-47
60-82
97-118
139-159
180-202
292-314
325-347</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.98</theoretical-pi>
    <molecular-weight>41681.57</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5291</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1E</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M91467</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>177774</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28566</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1E_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1E</synonym>
      <synonym>S31</synonym>
      <synonym>Serotonin receptor 1E</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010335|5-hydroxytryptamine receptor 1E
MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYL
ICSLAVTDLLVAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDR
YWAITNAIEYARKRTAKRAALMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHV
IYTIYSTLGAFYIPLTLILILYYRIYHAAKSLYQKRGSSRHLSNRSTDSQNSFASCKLTQ
TFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQISSTRERKAARILGLILGAF
ILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIR
CREHT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010336|5-hydroxytryptamine receptor 1E (HTR1E)
ATGAACATCACAAACTGTACCACAGAGGCCAGCATGGCTATAAGACCCAAGACCATCACT
GAGAAGATGCTCATTTGCATGACTCTGGTGGTCATCACCACCCTCACCACGTTGCTGAAC
TTGGCTGTGATCATGGCTATTGGCACCACCAAGAAGCTCCACCAGCCTGCCAACTACCTA
ATCTGTTCTCTGGCCGTGACGGACCTCCTGGTGGCAGTGCTCGTCATGCCCCTGAGCATC
ATCTACATTGTCATGGATCGCTGGAAGCTTGGGTACTTCCTCTGTGAGGTGTGGCTGAGT
GTGGACATGACCTGCTGCACCTGCTCCATCCTCCACCTCTGTGTCATTGCCCTGGACAGG
TACTGGGCCATCACCAATGCTATTGAATACGCCAGGAAGAGGACGGCCAAGAGGGCCGCG
CTGATGATCCTTACCGTCTGGACCATCTCCATTTTCATCTCCATGCCCCCTCTGTTCTGG
AGAAGCCACCGCCGCCTAAGCCCTCCCCCTAGTCAGTGCACCATCCAGCACGACCATGTT
ATCTACACCATTTACTCCACGCTGGGTGCGTTTTATATCCCCTTGACTTTGATACTGATT
CTCTATTACCGGATTTACCACGCGGCCAAGAGCCTTTACCAGAAAAGGGGATCAAGTCGG
CACTTAAGCAACAGAAGCACAGATAGCCAGAATTCTTTTGCAAGTTGTAAACTTACACAG
ACTTTCTGTGTGTCTGACTTCTCCACCTCAGACCCTACCACAGAGTTTGAAAAGTTCCAT
GCCTCCATCAGGATCCCCCCCTTCGACAATGATCTAGATCACCCAGGAGAACGTCAGCAG
ATCTCTAGCACCAGGGAACGGAAGGCAGCACGCATCCTGGGGCTGATTCTGGGTGCATTC
ATTTTATCCTGGCTGCCATTTTTCATCAAAGAGTTGATTGTGGGTCTGAGCATCTACACC
GTGTCCTCGGAAGTGGCCGACTTTCTGACGTGGCTCGGTTATGTGAATTCTCTGATCAAC
CCTCTGCTCTATACGAGTTTTAATGAAGACTTTAAGCTGGCTTTTAAAAAGCTCATTAGA
TGCCGAGAGCATACTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cAMP metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P30939" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 1F</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.</specific-function>
    <gene-name>HTR1F</gene-name>
    <locus>3p12</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>30-50
61-83
98-118
141-161
179-201
291-311
330-350</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.08</theoretical-pi>
    <molecular-weight>41708.505</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5292</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR1F</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L05597</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307420</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P30939</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT1F_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1F</synonym>
      <synonym>HTR1EL</synonym>
      <synonym>Serotonin receptor 1F</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010323|5-hydroxytryptamine receptor 1F
MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANY
LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD
RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV
STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS
VSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG
AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK
LVRCRC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010324|5-hydroxytryptamine receptor 1F (HTR1F)
ATGGATTTCTTAAATTCATCTGATCAAAACTTGACCTCAGAGGAACTGTTAAACAGAATG
CCATCCAAAATTCTGGTGTCCCTCACTCTGTCTGGGCTGGCACTGATGACAACAACTATC
AACTCCCTTGTGATCGCTGCAATTATTGTGACCCGGAAGCTGCACCATCCAGCCAATTAT
TTAATTTGTTCCCTTGCAGTCACAGATTTTCTTGTGGCTGTCCTGGTGATGCCCTTCAGC
ATTGTGTATATTGTGAGAGAGAGCTGGATTATGGGGCAAGTGGTCTGTGACATTTGGCTG
AGTGTTGACATTACCTGCTGCACGTGCTCCATCTTGCATCTCTCAGCTATAGCTTTGGAT
CGGTATCGAGCAATCACAGATGCTGTTGAGTATGCCAGGAAAAGGACTCCAAAGCATGCT
GGCATTATGATTACAATAGTTTGGATTATATCTGTTTTTATCTCTATGCCTCCTCTATTC
TGGAGGCACCAAGGAACTAGCAGAGATGATGAATGCATCATCAAGCACGACCACATTGTT
TCCACCATTTACTCAACATTTGGAGCTTTCTACATCCCACTGGCATTGATTTTGATCCTT
TACTACAAAATATATAGAGCAGCAAAGACATTATACCACAAGAGACAAGCAAGTAGGATT
GCAAAGGAGGAGGTGAATGGCCAAGTCCTTTTGGAGAGTGGTGAGAAAAGCACTAAATCA
GTTTCCACATCCTATGTACTAGAAAAGTCTTTATCTGACCCATCAACAGACTTTGATAAA
ATTCATAGCACAGTGAGAAGTCTCAGGTCTGAATTCAAGCATGAGAAATCTTGGAGAAGG
CAAAAGATCTCAGGTACAAGAGAACGGAAAGCAGCCACTACCCTGGGATTAATCTTGGGT
GCATTTGTAATATGTTGGCTTCCTTTTTTTGTAAAAGAATTAGTTGTTAATGTCTGTGAC
AAATGTAAAATTTCTGAAGAAATGTCCAATTTTTTGGCATGGCTTGGGTATCTCAATTCC
CTTATAAATCCACTGATTTACACAATCTTTAATGAAGACTTCAAGAAAGCATTCCAAAAG
CTTGTGCGATGTCGATGTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P28223" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 2A</name>
    <general-function>Virus receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.</specific-function>
    <gene-name>HTR2A</gene-name>
    <locus>13q14-q21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>76-99
111-132
149-171
192-215
234-254
325-346
363-384</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.72</theoretical-pi>
    <molecular-weight>52602.58</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5293</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>S42168</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>36431</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28223</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-2</synonym>
      <synonym>HTR2</synonym>
      <synonym>Serotonin receptor 2A</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000899|5-hydroxytryptamine receptor 2A
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC
LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD
MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP
IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF
VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH
REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA
LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020465|5-hydroxytryptamine receptor 2A (HTR2A)
ATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAA
TTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAAGCTAACACTTCT
GATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGC
CTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTG
ACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCC
CTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTTGCCATAGCTGAT
ATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTGTATGGGTACCGG
TGGCCTCTGCCGAGCAAGCTTTGTGCAGTCTGGATTTACCTGGACGTGCTCTTCTCCACG
GCCTCCATCATGCACCTCTGCGCCATCTCGCTGGACCGCTACGTCGCCATCCAGAATCCC
ATCCACCACAGCCGCTTCAACTCCAGAACTAAGGCATTTCTGAAAATCATTGCTGTTTGG
ACCATATCAGTAGGTATATCCATGCCAATACCAGTCTTTGGGCTACAGGACGATTCGAAG
GTCTTTAAGGAGGGGAGTTGCTTACTCGCCGATGATAACTTTGTCCTGATCGGCTCTTTT
GTGTCATTTTTCATTCCCTTAACCATCATGGTGATCACCTACTTTCTAACTATCAAGTCA
CTCCAGAAAGAAGCTACTTTGTGTGTAAGTGATCTTGGCACACGGGCCAAATTAGCTTCT
TTCAGCTTCCTCCCTCAGAGTTCTTTGTCTTCAGAAAAGCTCTTCCAGCGGTCGATCCAT
AGGGAGCCAGGGTCCTACACAGGCAGGAGGACTATGCAGTCCATCAGCAATGAGCAAAAG
GCATGCAAGGTGCTGGGCATCGTCTTCTTCCTGTTTGTGGTGATGTGGTGCCCTTTCTTC
ATCACAAACATCATGGCCGTCATCTGCAAAGAGTCCTGCAATGAGGATGTCATTGGGGCC
CTGCTCAATGTGTTTGTTTGGATCGGTTATCTCTCTTCAGCAGTCAACCCACTAGTCTAC
ACACTGTTCAACAAGACCTATAGGTCAGCCTTTTCACGGTATATTCAGTGTCAGTACAAG
GAAAACAAAAAACCATTGCAGTTAATTTTAGTGAACACAATACCGGCTTTGGCCTACAAG
TCTAGCCAACTTCAAATGGGACAAAAAAAGAATTCAAAGCAAGATGCCAAGACAACAGAT
AATGACTGCTCAATGGTTGCTCTAGGAAAGCAGCATTCTGAAGAGGCTTCTAAAGACAAT
AGCGACGGAGTGAATGAAAAGGTGAGCTGTGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell body fiber</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendritic shaft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bounded vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>virus receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>temperature homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycolytic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sleep</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dopamine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of mechanical stimulus involved in sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urinary bladder smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to cytoskeleton</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of temperature stimulus involved in sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>artery smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P41595" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 2B</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine.</specific-function>
    <gene-name>HTR2B</gene-name>
    <locus>2q36.3-q37.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>57-79
91-113
130-151
172-192
217-239
325-345
361-382</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.47</theoretical-pi>
    <molecular-weight>54297.41</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5294</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X77307</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>475198</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P41595</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-2B</synonym>
      <synonym>Serotonin receptor 2B</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016078|5-hydroxytryptamine receptor 2B
MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALL
ILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAM
WPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVW
LISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLT
IHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDET
LMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQM
LLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNP
MAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSY
V</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016079|5-hydroxytryptamine receptor 2B (HTR2B)
ATGGCTCTCTCTTACAGAGTGTCTGAACTTCAAAGCACAATTCCTGAGCACATTTTGCAG
AGCACCTTTGTTCACGTTATCTCTTCTAACTGGTCTGGATTACAGACAGAATCAATACCA
GAGGAAATGAAACAGATTGTTGAGGAACAGGGAAATAAACTGCACTGGGCAGCTCTTCTG
ATACTCATGGTGATAATACCCACAATTGGTGGAAATACCCTTGTTATTCTGGCTGTTTCA
CTGGAGAAGAAGCTGCAGTATGCTACTAATTACTTTCTAATGTCCTTGGCGGTGGCTGAT
TTGCTGGTTGGATTGTTTGTGATGCCAATTGCCCTCTTGACAATAATGTTTGAGGCTATG
TGGCCCCTCCCACTTGTTCTATGTCCTGCCTGGTTATTTCTTGACGTTCTCTTTTCAACC
GCATCCATCATGCATCTCTGTGCCATTTCAGTGGATCGTTACATAGCCATCAAAAAGCCA
ATCCAGGCCAATCAATATAACTCACGGGCTACAGCATTCATCAAGATTACAGTGGTGTGG
TTAATTTCAATAGGCATTGCCATTCCAGTCCCTATTAAAGGGATAGAGACTGATGTGGAC
AACCCAAACAATATCACTTGTGTGCTGACAAAGGAACGTTTTGGCGATTTCATGCTCTTT
GGCTCACTGGCTGCCTTCTTCACACCTCTTGCAATTATGATTGTCACCTACTTTCTCACT
ATCCATGCTTTACAGAAGAAGGCTTACTTAGTCAAAAACAAGCCACCTCAACGCCTAACA
TGGTTGACTGTGTCTACAGTTTTCCAAAGGGATGAAACACCTTGCTCGTCACCGGAAAAG
GTGGCAATGCTGGATGGTTCTCGAAAGGACAAGGCTCTGCCCAACTCAGGTGATGAAACA
CTTATGCGAAGAACATCCACAATTGGGAAAAAGTCAGTGCAGACCATTTCCAACGAACAG
AGAGCCTCAAAGGTCCTAGGGATTGTGTTTTTCCTCTTTTTGCTTATGTGGTGTCCCTTC
TTTATTACAAATATAACTTTAGTTTTATGTGATTCCTGTAACCAAACTACTCTCCAAATG
CTCCTGGAGATATTTGTGTGGATAGGCTATGTTTCCTCAGGAGTGAATCCTTTGGTCTAC
ACCCTCTTCAATAAGACATTTCGGGATGCATTTGGCCGATATATCACCTGCAATTACCGG
GCCACAAAGTCAGTAAAAACTCTCAGAAAACGCTCCAGTAAGATCTACTTCCGGAATCCA
ATGGCAGAGAACTCTAAGTTTTTCAAGAAACATGGAATTCGAAATGGGATTAACCCTGCC
ATGTACCAGAGTCCAATGAGGCTCCGAAGTTCAACCATTCAGTCTTCATCAATCATTCTA
CTAGATACGCTTCTCCTCACTGAAAATGAAGGTGACAAAACTGAAGAGCAAGTTAGTTAT
GTATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein alpha-subunit binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>GTPase activator activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of autophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to temperature stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hepatic stellate cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cGMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inositol phosphate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric-oxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neural crest cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiac muscle hypertrophy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neural crest cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intestine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of endothelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heart morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to amine stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to serotonin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P28335" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 2C</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.</specific-function>
    <gene-name>HTR2C</gene-name>
    <locus>Xq24</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>53-78
90-110
128-150
171-193
214-235
312-333
349-371</transmembrane-regions>
    <signal-regions>1-32</signal-regions>
    <theoretical-pi>9.11</theoretical-pi>
    <molecular-weight>51820.705</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5295</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M81778</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>338028</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P28335</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-1C</synonym>
      <synonym>5-HT-2C</synonym>
      <synonym>5-HT1C</synonym>
      <synonym>5-hydroxytryptamine receptor 1C</synonym>
      <synonym>HTR1C</synonym>
      <synonym>Serotonin receptor 2C</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001064|5-hydroxytryptamine receptor 2C
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C)
ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT
TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC
TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC
GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG
GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG
CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG
CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG
TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT
GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA
ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG
TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC
GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT
CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT
CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT
AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG
CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT
CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC
TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT
TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC
AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA
GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT
GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT
TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>Gq/11-coupled serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>feeding behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cGMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of appetite</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of corticotropin-releasing hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>release of sequestered calcium ion into cytosol</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P46098" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 3A</name>
    <general-function>Voltage-gated potassium channel activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
    <gene-name>HTR3A</gene-name>
    <locus>11q23.1</locus>
    <cellular-location>Cell junction</cellular-location>
    <transmembrane-regions>242-268
274-292
303-321
456-475</transmembrane-regions>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.43</theoretical-pi>
    <molecular-weight>55279.835</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5297</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR3A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D49394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>681914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>373</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P46098</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT3A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-3</synonym>
      <synonym>5-HT3-A</synonym>
      <synonym>5-HT3R</synonym>
      <synonym>5-hydroxytryptamine receptor 3</synonym>
      <synonym>5HT3R</synonym>
      <synonym>HTR3</synonym>
      <synonym>Serotonin receptor 3A</synonym>
      <synonym>Serotonin-gated ion channel receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000619|5-hydroxytryptamine receptor 3A
MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTT
VSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDI
LINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLH
TIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRR
RPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAI
GTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQ
STSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQ
ELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010242|5-hydroxytryptamine receptor 3A (HTR3A)
ATGCTTGGAAAGCTCGCTATGCTGCTGTGGGTCCAGCAGGCGCTGCTCGCCTTGCTCCTC
CCCACACTCCTGGCACAGGGAGAAGCCAGGAGGAGCCGAAACACCACCAGGCCCGCTCTG
CTGAGGCTGTCGGATTACCTTTTGACCAACTACAGGAAGGGTGTGCGCCCCGTGAGGGAC
TGGAGGAAGCCAACCACCGTATCCATTGACGTCATTGTCTATGCCATCCTCAACGTGGAT
GAGAAGAATCAGGTGCTGACCACCTACATCTGGTACCGGCAGTACTGGACTGATGAGTTT
CTCCAGTGGAACCCTGAGGACTTTGACAACATCACCAAGTTGTCCATCCCCACGGACAGC
ATCTGGGTCCCGGACATTCTCATCAATGAGTTCGTGGATGTGGGGAAGTCTCCAAATATC
CCGTACGTGTATATTCGGCATCAAGGCGAAGTTCAGAACTACAAGCCCCTTCAGGTGGTG
ACTGCCTGTAGCCTCGACATCTACAACTTCCCCTTCGATGTCCAGAACTGCTCGCTGACC
TTCACCAGTTGGCTGCACACCATCCAGGACATCAACATCTCTTTGTGGCGCTTGCCAGAA
AAGGTGAAATCCGACAGGAGTGTCTTCATGAACCAGGGAGAGTGGGAGTTGCTGGGGGTG
CTGCCCTACTTTCGGGAGTTCAGCATGGAAAGCAGTAACTACTATGCAGAAATGAAGTTC
TATGTGGTCATCCGCCGGCGGCCCCTCTTCTATGTGGTCAGCCTGCTACTGCCCAGCATC
TTCCTCATGGTCATGGACATCGTGGGCTTCTACCTGCCCCCCAACAGTGGCGAGAGGGTC
TCTTTCAAGATTACACTCCTCCTGGGCTACTCGGTCTTCCTGATCATCGTTTCTGACACG
CTGCCGGCCACTGCCATCGGCACTCCTCTCATTGGTGTCTACTTTGTGGTGTGCATGGCT
CTGCTGGTGATAAGTTTGGCCGAGACCATCTTCATTGTGCGGCTGGTGCACAAGCAAGAC
CTGCAGCAGCCCGTGCCTGCTTGGCTGCGTCACCTGGTTCTGGAGAGAATCGCCTGGCTA
CTTTGCCTGAGGGAGCAGTCAACTTCCCAGAGGCCCCCAGCCACCTCCCAAGCCACCAAG
ACTGATGACTGCTCAGCCATGGGAAACCACTGCAGCCACATGGGAGGACCCCAGGACTTC
GAGAAGAGCCCGAGGGACAGATGTAGCCCTCCCCCACCACCTCGGGAGGCCTCGCTGGCG
GTGTGTGGGCTGCTGCAGGAGCTGTCCTCCATCCGGCAATTCCTGGAAAAGCGGGATGAG
ATCCGAGAGGTGGCCCGAGACTGGCTGCGCGTGGGCTCCGTGCTGGACAAGCTGCTATTC
CACATTTACCTGCTAGCGGTGCTGGCCTACAGCATCACCCTGGTTATGCTCTGGTCCATC
TGGCAGTACGCTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF02931</identifier>
        <name>Neur_chan_LBD</name>
      </pfam>
      <pfam>
        <identifier>PF02932</identifier>
        <name>Neur_chan_memb</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>postsynaptic membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin-activated cation-selective channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>voltage-gated potassium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cation transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="O95264" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 3B</name>
    <general-function>Serotonin-activated cation-selective channel activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
    <gene-name>HTR3B</gene-name>
    <locus/>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>239-259
269-286
304-324
415-435</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi/>
    <molecular-weight>50291.3</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5298</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O95264</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT3B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT3-B</synonym>
      <synonym>Serotonin receptor 3B</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008660|5-hydroxytryptamine receptor 3B
MLSSVMAPLWACILVAAGILATDTHHPQDSALYHLSKQLLQKYHKEVRPVYNWTKATTVY
LDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAIWAPDIII
NEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQNCSLTFKSILHTV
EDVDLAFLRSPEDIQHDKKAFLNDSEWELLSVSSTYSILQSSAGGFAQIQFNVVMRRHPL
VYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTVFRVNMSNQVPRSVGSTP
LIGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQPFLCLRGDTDADRPRVEPRAQRA
VVTESSLYGEHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSY
LFMLGIYTITLCSLWALWGGV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019637|5-hydroxytryptamine receptor 3B (HTR3B)
ATGTTGTCAAGTGTAATGGCTCCCCTGTGGGCCTGCATCCTGGTGGCTGCAGGAATTCTA
GCCACAGATACACATCATCCCCAGGATTCTGCTCTGTATCATCTCAGCAAGCAGCTATTA
CAGAAATATCATAAAGAAGTGAGACCTGTTTACAACTGGACCAAGGCCACCACAGTCTAC
CTGGACCTGTTCGTCCATGCTATATTGGATGTGGATGCAGAGAATCAAATATTAAAGACA
AGTGTATGGTACCAAGAGGTCTGGAATGATGAATTTTTATCCTGGAACTCCAGCATGTTT
GATGAGATTAGAGAGATCTCCCTACCTCTAAGTGCCATCTGGGCCCCCGATATCATCATC
AATGAGTTTGTGGACATTGAAAGATACCCTGACCTTCCCTATGTTTATGTGAACTCATCT
GGGACCATTGAGAACTATAAGCCCATCCAGGTGGTCTCTGCGTGCAGTTTAGAGACATAT
GCTTTTCCATTTGATGTCCAGAATTGCAGCCTGACCTTCAAGAGCATTCTGCATACAGTG
GAAGACGTAGACCTGGCCTTTCTGAGGAGCCCAGAAGACATTCAGCATGACAAAAAGGCG
TTTTTGAATGACAGTGAGTGGGAACTTCTATCTGTGTCCTCCACATACAGCATCCTGCAG
AGCAGCGCTGGAGGATTTGCACAGATTCAGTTTAATGTGGTGATGCGCAGGCACCCCCTG
GTCTATGTCGTGAGTCTGCTGATTCCTAGCATCTTTCTCATGCTGGTGGACCTGGGGAGC
TTCTACCTGCCACCCAACTGCCGAGCCAGGATTGTGTTCAAGACCAGTGTGCTGGTGGGC
TACACCGTCTTCAGGGTCAACATGTCCAACCAGGTGCCACGGAGTGTAGGGAGCACCCCT
CTGATTGGGCACTTCTTCACCATCTGCATGGCCTTCTTGGTTCTCAGCTTAGCTAAGTCC
ATCGTGTTGGTCAAATTCCTCCATGATGAGCAGCGTGGTGGACAGGAGCAGCCCTTCTTG
TGCCTTCGAGGGGACACCGATGCTGACAGGCCTAGAGTGGAACCCAGGGCCCAACGTGCT
GTGGTAACAGAGTCCTCGCTGTATGGAGAGCACCTGGCCCAGCCAGGAACCCTGAAGGAA
GTCTGGTCGCAGCTTCAATCTATCAGCAACTACCTCCAAACTCAGGACCAGACAGACCAA
CAGGAGGCAGAGTGGCTGGTCCTCCTGTCCCGCTTTGACCGACTGCTCTTCCAAAGCTAC
CTTTTCATGCTGGGGATCTACACCATCACTCTGTGCTCCCTCTGGGCACTGTGGGGCGGC
GTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF02931</identifier>
        <name>Neur_chan_LBD</name>
      </pfam>
      <pfam>
        <identifier>PF02932</identifier>
        <name>Neur_chan_memb</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>postsynaptic membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ion channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin-activated cation-selective channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cation transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="Q8WXA8" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 3C</name>
    <general-function>Serotonin-activated cation-selective channel activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
    <gene-name>HTR3C</gene-name>
    <locus/>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>249-269
283-303
307-329
425-445</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi/>
    <molecular-weight>50219.07</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:24003</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q8WXA8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT3C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT3-C</synonym>
      <synonym>Serotonin receptor 3C</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017548|5-hydroxytryptamine receptor 3C
MEGGWPARQSALLCLTVSLLLQGRGDAFTINCSGFDQHGVDPAVFQAVFDRKAFRPFTNY
SIPTRVNISFTLSAILGVDAQLQLLTSFLWMDLVWDNPFINWNPKECVGINKLTVLAENL
WLPDIFIVESMDVDQTPSGLTAYISSEGRIKYDKPMRVTSICNLDIFYFPFDQQNCTFTF
SSFLYTVDSMLLGMDKEVWEITDTSRKVIQTQGEWELLGINKATPKMSMGNNLYDQIMFY
VAIRRRPSLYIINLLVPSSFLVAIDALSFYLPAESENRAPFKITLLLGYNVFLLMMNDLL
PASGTPLISVYFALCLSLMVVSLLETVFITYLLHVATTQPPPMPRWLHSLLLHCTSPGRC
CPTAPQKGNKGLGLTLTHLPGPKEPGELAGKKLGPRETEPDGGSGWTKTQLMELWVQFSH
AMDTLLFRLYLLFMASSILTVIVLWNT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0017549|5-hydroxytryptamine receptor 3C (HTR3C)
ATGGAAGGAGGGTGGCCTGCAAGGCAGAGTGCCCTCCTCTGCCTCACTGTCAGTCTTCTG
CTTCAAGGAAGAGGCGACGCTTTTACCATCAATTGCTCAGGCTTTGACCAGCATGGGGTT
GACCCTGCTGTCTTCCAAGCAGTGTTTGACAGAAAGGCCTTCCGTCCATTCACCAACTAC
AGCATCCCTACCCGTGTCAACATCTCCTTCACCCTGTCTGCCATCCTGGGAGTGGATGCA
CAGCTCCAGCTGCTGACATCATTCCTGTGGATGGATTTGGTATGGGACAATCCTTTCATT
AATTGGAACCCAAAAGAGTGTGTTGGCATCAATAAACTCACAGTATTAGCTGAAAACCTG
TGGCTCCCAGACATCTTCATCGTGGAATCCATGGATGTGGATCAGACGCCTTCCGGTCTC
ACTGCCTATATCAGCAGTGAAGGTCGAATTAAGTATGATAAGCCAATGAGGGTGACCAGC
ATCTGTAACCTGGACATCTTCTACTTCCCTTTTGACCAACAGAACTGTACCTTCACCTTC
AGTTCTTTCCTCTACACAGTGGACAGCATGCTGCTGGGCATGGACAAGGAGGTGTGGGAG
ATCACAGACACGTCTCGCAAAGTCATCCAAACCCAGGGGGAGTGGGAGCTCTTGGGCATC
AACAAGGCCACCCCAAAGATGTCCATGGGCAACAACCTATATGACCAGATCATGTTTTAT
GTGGCCATCAGGCGCAGGCCAAGCCTCTACATCATAAACCTGCTGGTGCCCAGTAGCTTT
CTGGTTGCCATTGATGCCCTCAGCTTCTACCTGCCAGCAGAGAGCGAGAATCGTGCCCCA
TTCAAGATAACACTTCTGCTGGGCTACAACGTCTTCCTGCTCATGATGAATGACTTGCTC
CCTGCCAGTGGCACCCCCCTCATCAGTGTCTACTTCGCCCTGTGCCTGTCCCTGATGGTG
GTCAGCCTGCTGGAGACCGTCTTCATTACCTACCTGCTGCACGTGGCCACCACCCAGCCC
CCACCCATGCCTAGGTGGCTTCACTCCCTGCTGCTCCACTGCACCAGCCCAGGGAGATGC
TGTCCCACTGCGCCCCAGAAGGGAAATAAGGGCCTGGGTCTCACCCTCACCCACCTGCCT
GGCCCAAAGGAGCCGGGGGAGTTAGCAGGGAAGAAGCTGGGACCCAGAGAGACCGAGCCA
GATGGGGGCTCAGGATGGACAAAGACCCAGCTAATGGAGCTGTGGGTGCAGTTCAGCCAC
GCGATGGACACCCTGCTCTTCCGCCTCTACCTGCTCTTCATGGCCTCCTCCATCCTTACT
GTCATTGTCCTCTGGAACACCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF02931</identifier>
        <name>Neur_chan_LBD</name>
      </pfam>
      <pfam>
        <identifier>PF02932</identifier>
        <name>Neur_chan_memb</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin-activated cation-selective channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cation transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="Q70Z44" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 3D</name>
    <general-function>Serotonin-activated cation-selective channel activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
    <gene-name>HTR3D</gene-name>
    <locus/>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>233-253
265-285
307-327
432-452</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi/>
    <molecular-weight>50190.625</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:24004</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q70Z44</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT3D_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT3-D</synonym>
      <synonym>Serotonin receptor 3D</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008662|5-hydroxytryptamine receptor 3D
MQKHSPGPPALALLSQSLLTTGNGDTLIINCPGFGQHRVDPAAFQAVFDRKAIGPVTNYS
VATHVNISFTLSAIWNCYSRIHTFNCHHARPWHNQFVQWNPDECGGIKKSGMATENLWLS
DVFIEESVDQTPAGLMASMSIVKATSNTISQCGWSASANWTPSISPSMDRARAWRRMSRS
FQIHHRTSFRTRREWVLLGIQKRTIKVTVATNQYEQAIFHVAIRRRCRPSPYVVNFLVPS
GILIAIDALSFYLPLESGNCAPFKMTVLLGYSVFLLMMNDLLPATSTSSHASLVAPLALM
QTPLPAGVYFALCLSLMVGSLLETIFITHLLHVATTQPLPLPRWLHSLLLHCTGQGRCCP
TAPQKGNKGPGLTPTHLPGVKEPEVSAGQMPGPGEAELTGGSEWTRAQREHEAQKQHSVE
LWVQFSHAMDALLFRLYLLFMASSIITVICLWNT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0013339|5-hydroxytryptamine receptor 3D (HTR3D)
ATGGAAAGAGGCTGGTTCCATGGGAAAGGATTCCTCCTTGGCTTCATCCTCCACCTGCTG
CTGCAAGATTCACACCTTCAACTGGTGACATCGTTCCTGTGGCTAAATATGTGGAACCCA
GATGAATGCGGAGGCATCAAGAAGTCCGGCATGGCAACTGAGAACCTATGGCTTTCAGAT
GTCTTCATCGAGGAGTCTGTGGATCAGACACCTGCAGGTCTCATGGCTAGTATGTCAATA
GTGAAGGCCACATCAAACACAATAAGCCAATGTGGGTGGTCAGCATCTGCAAACTGGACA
CCTTCTATTTCCCCTTCCATGGACAGAGGTGAACGCTCTCCTTCAGCCCTTTCACCTACA
CAGGTAACCCGGGCATGGAGAAGGATGTCCAGGAGCTTTCAAATACATCACAGAACCTCA
TTCAGAACAAGGAGGGAGTGGGTACTGCTGGGTATCCAAAAAAGAACAATAAAGGTGACC
GTGGCCACTAACCAGTATGAACAAGCCATCTTCCATGTGGCCATCAGGCGCAGGTGCAGG
CCCAGCCCCTACGTGGTAAACTTTCTGGTGCCCAGTGGCATTCTGATTGCCATCGATGCC
CTCAGTTTCTACCTGCCACTGGAAAGTGGGAATTGTGCCCCATTCAAGATGACTGTTCTG
CTGGGCTACAGCGTCTTCCTGCTCATGATGAATGACTTGCTCCCAGCCACTAGCACTTCA
TCACATGCTTCACTAGTACGTCCTCATCCATCAAGAGACCAAAAGCGAGGTGTCTACTTC
GCCCTGTGCCTGTCCCTGATGGTGGGCAGCCTGCTGGAGACCATCTTCATCACCCACCTG
CTGCACGTGGCCACCACCCAGCCCCTACCTCTGCCTCGGTGGCTCCACTCCCTGCTGCTG
CACTGCACCGGCCAAGGGAGATGCTGTCCCACTGCGCCCCAGAAGGGAAATAAGGGCCCG
GGTCTCACCCCCACCCACCTGCCCGGTGTGAAGGAGCCAGAGGTATCAGCAGGGCAGATG
CCAGGCCCTGGGGAGGCAGAGCTGACAGGGGGCTCAGAATGGACAAGGGCCCAGCGGGAA
CACGAGGCCCAGAAGCAGCACTCGGTGGAGCTGTGGGTGCAGTTCAGCCACGCGATGGAC
GCCCTGCTCTTCCGCCTCTACCTGCTCTTCATGGCCTCCTCCATCATCACCGTCATATGC
CTCTGGAACACCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF02931</identifier>
        <name>Neur_chan_LBD</name>
      </pfam>
      <pfam>
        <identifier>PF02932</identifier>
        <name>Neur_chan_memb</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin-activated cation-selective channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cation transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="A5X5Y0" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 3E</name>
    <general-function>Serotonin-activated cation-selective channel activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
    <gene-name>HTR3E</gene-name>
    <locus/>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>249-269
283-303
308-328
434-454</transmembrane-regions>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi/>
    <molecular-weight>51437.415</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:24005</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>A5X5Y0</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT3E_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT3-E</synonym>
      <synonym>Serotonin receptor 3E</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008663|5-hydroxytryptamine receptor 3E
MEGSWFHRKRFSFYLLLGFLLQGRGVTFTINCSGFGQHGADPTALNSVFNRKPFRPVTNI
SVPTQVNISFAMSAILDVNEQLHLLSSFLWLEMVWDNPFISWNPEECEGITKMSMAAKNL
WLPDIFIIELMDVDKTPKGLTAYVSNEGRIRYKKPMKVDSICNLDIFYFPFDQQNCTLTF
SSFLYTVDSMLLDMEKEVWEITDASRNILQTHGEWELLGLSKATAKLSRGGNLYDQIVFY
VAIRRRPSLYVINLLVPSGFLVAIDALSFYLPVKSGNRVPFKITLLLGYNVFLLMMSDLL
PTSGTPLIGVYFALCLSLMVGSLLETIFITHLLHVATTQPPPLPRWLHSLLLHCNSPGRC
CPTAPQKENKGPGLTPTHLPGVKEPEVSAGQMPGPAEAELTGGSEWTRAQREHEAQKQHS
VELWLQFSHAMDAMLFRLYLLFMASSIITVICLWNT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021420|5-hydroxytryptamine receptor 3E (HTR3E)
ATGGAAGGAAGCTGGTTCCACAGGAAAAGATTTTCCTTCTACCTCCTTCTCGGTTTTCTG
CTTCAAGGAAGGGGCGTTACTTTCACCATCAATTGCTCAGGGTTTGGCCAGCACGGGGCG
GATCCCACTGCTCTGAATTCAGTGTTTAATAGAAAGCCCTTCCGTCCGGTCACCAACATC
AGCGTCCCCACCCAAGTCAACATCTCCTTCGCGATGTCTGCCATCCTAGATGTGAATGAA
CAGCTGCACCTCTTGTCATCATTCCTGTGGCTGGAAATGGTTTGGGATAACCCATTTATC
AGCTGGAACCCAGAGGAATGTGAGGGCATCACGAAGATGAGTATGGCAGCCAAGAACCTG
TGGCTCCCAGACATTTTCATCATTGAACTCATGGATGTGGATAAGACCCCAAAAGGCCTC
ACAGCATATGTAAGTAATGAAGGTCGCATCAGGTATAAGAAACCCATGAAGGTGGACAGT
ATCTGTAACCTGGACATCTTCTACTTCCCCTTCGACCAGCAGAACTGCACACTCACCTTC
AGCTCATTCCTCTACACAGTGGACAGCATGTTGCTGGACATGGAGAAAGAAGTGTGGGAA
ATAACAGACGCATCCCGGAACATCCTTCAGACCCATGGAGAATGGGAGCTCCTGGGCCTC
AGCAAGGCCACCGCAAAGTTGTCCAGGGGAGGCAACCTGTATGATCAGATCGTGTTCTAT
GTGGCCATCAGGCGCAGGCCCAGTCTCTATGTCATAAACCTTCTCGTGCCCAGTGGCTTT
CTGGTTGCCATCGATGCCCTCAGCTTCTACCTGCCAGTGAAAAGTGGGAATCGTGTCCCA
TTCAAGATAACGCTCCTGCTGGGCTACAACGTCTTCCTGCTCATGATGAGTGACTTGCTC
CCCACCAGTGGCACCCCCCTCATCGGTGTCTACTTCGCCCTGTGCCTGTCCCTGATGGTG
GGCAGCCTGCTGGAGACCATCTTCATCACCCACCTGCTGCACGTGGCCACCACCCAGCCC
CCACCCCTGCCTCGGTGGCTCCACTCCCTGCTGCTCCACTGCAACAGCCCGGGGAGATGC
TGTCCCACTGCGCCCCAGAAGGAAAATAAGGGCCCGGGTCTCACCCCCACCCACCTGCCC
GGTGTGAAGGAGCCAGAGGTATCAGCAGGGCAGATGCCGGGCCCTGCGGAGGCAGAGCTG
ACAGGGGGCTCAGAATGGACAAGGGCCCAGCGGGAACACGAGGCCCAGAAGCAGCACTCA
GTGGAGCTGTGGTTGCAGTTCAGCCACGCGATGGACGCCATGCTCTTCCGCCTCTACCTG
CTCTTCATGGCCTCCTCTATCATCACCGTCATATGCCTCTGGAACACCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF02931</identifier>
        <name>Neur_chan_LBD</name>
      </pfam>
      <pfam>
        <identifier>PF02932</identifier>
        <name>Neur_chan_memb</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin-activated cation-selective channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of membrane potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cation transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurological system process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ion transmembrane transport</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="Q13639" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 4</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.</specific-function>
    <gene-name>HTR4</gene-name>
    <locus>5q31-q33</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>20-40
59-79
94-116
138-158
193-213
261-281
295-315</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.82</theoretical-pi>
    <molecular-weight>43760.975</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5299</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Y12505</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>2661757</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>9</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>9</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q13639</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT4R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-4</synonym>
      <synonym>Serotonin receptor 4</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000168|5-hydroxytryptamine receptor 4
MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIV
SLAFADLLVSVLVMPFGAIELVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYY
AICCQPLVYRNKMTPLRIALMLGGCWVIPTFISFLPIMQGWNNIGIIDLIEKRKFNQNSN
STYCVFMVNKPYAITCSVVAFYIPFLLMVLAYYRIYVTAKEHAHQIQMLQRAGASSESRP
QSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWL
GYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRD
AVECGGQWESQCHPPATSPLVAAQPSDT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0009924|5-hydroxytryptamine receptor 4 (HTR4)
ATGGACAAACTTGATGCTAATGTGAGTTCTGAGGAGGGTTTCGGGTCAGTGGAGAAGGTG
GTGCTGCTCACGTTTCTCTCGACGGTTATCCTGATGGCCATCTTGGGGAACCTGCTGGTG
ATGGTGGCTGTGTGCTGGGACAGGCAGCTCAGGAAAATAAAAACAAATTATTTCATTGTA
TCTCTTGCTTTTGCGGATCTGCTGGTTTCGGTGCTGGTGATGCCCTTTGGTGCCATTGAG
CTGGTTCAAGACATCTGGATTTATGGGGAGGTGTTTTGTCTTGTTCGGACATCTCTGGAC
GTCCTGCTCACAACGGCATCGATTTTTCACCTGTGCTGCATTTCTCTGGATAGGTATTAC
GCCATCTGCTGCCAGCCTTTGGTCTATAGGAACAAGATGACCCCTCTGCGCATCGCATTA
ATGCTGGGAGGCTGCTGGGTCATCCCCACGTTTATTTCTTTTCTCCCTATAATGCAAGGC
TGGAATAACATTGGCATAATTGATTTGATAGAAAAGAGGAAGTTCAACCAGAACTCTAAC
TCTACGTACTGTGTCTTCATGGTCAACAAGCCCTACGCCATCACCTGCTCTGTGGTGGCC
TTCTACATCCCATTTCTCCTCATGGTGCTGGCCTATTACCGCATCTATGTCACAGCTAAG
GAGCATGCCCATCAGATCCAGATGTTACAACGGGCAGGAGCCTCCTCCGAGAGCAGGCCT
CAGTCGGCAGACCAGCATAGCACTCATCGCATGAGGACAGAGACCAAAGCAGCCAAGACC
CTGTGCATCATCATGGGTTGCTTCTGCCTCTGCTGGGCACCATTCTTTGTCACCAATATT
GTGGATCCTTTCATAGACTACACTGTCCCTGGGCAGGTGTGGACTGCTTTCCTCTGGCTC
GGCTATATCAATTCCGGGTTGAACCCTTTTCTCTACGCCTTCTTGAATAAGTCTTTTAGA
CGTGCCTTCCTCATCATCCTCTGCTGTGATGATGAGCGCTACCGAAGACCTTCCATTCTG
GGCCAGACTGTCCCTTGTTCAACCACAACCATTAATGGATCCACACATGTACTAAGGGAT
GCAGTGGAGTGTGGTGGCCAGTGGGAGAGTCAGTGTCACCCGCCAGCAACTTCTCCTTTG
GTGGCTGCTCAGCCCAGTGACACTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of appetite</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gamma-aminobutyric acid signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P50406" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 6</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity (By similarity). Is an activator of TOR signaling (PubMed:23027611).</specific-function>
    <gene-name>HTR6</gene-name>
    <locus>1p36-p35</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>35-57
65-85
101-122
145-166
185-208
266-290
296-320</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.02</theoretical-pi>
    <molecular-weight>46953.625</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5301</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L41147</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1162924</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>11</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>11</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P50406</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT6R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-6</synonym>
      <synonym>Serotonin receptor 6</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010665|5-hydroxytryptamine receptor 6
MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNT
SNFFLVSLFTSDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLI
SLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQC
RLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQASETLQVP
RTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPG
LFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGP
RPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNF
FNIDPAEPELRPHPLGIPTN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010666|5-hydroxytryptamine receptor 6 (HTR6)
ATGGTCCCAGAGCCGGGCCCAACCGCCAATAGCACCCCGGCCTGGGGGGCAGGGCCGCCG
TCGGCCCCGGGGGGCAGCGGCTGGGTGGCGGCCGCGCTGTGCGTGGTCATCGCGCTGACG
GCGGCGGCCAACTCGCTGCTGATCGCGCTCATCTGCACTCAGCCCGCGCTGCGCAACACG
TCCAACTTCTTCCTGGTGTCGCTCTTCACGTCTGACCTGATGGTGGGGCTGGTGGTGATG
CCGCCGGCCATGCTGAACGCGCTGTACGGGCGCTGGGTGCTGGCGCGCGGCCTCTGCCTG
CTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCCTCAACCTCTGCCTCATC
AGCCTGGACCGCTACCTGCTCATCCTCTCGCCGCTGCGCTACAAGCTGCGCATGACGCCC
CTGCGTGCCCTGGCCCTAGTCCTGGGCGCCTGGAGCCTCGCCGCTCTCGCCTCCTTCCTG
CCCCTGCTGCTGGGCTGGCACGAGCTGGGCCACGCACGGCCACCCGTCCCTGGCCAGTGC
CGCCTGCTGGCCAGCCTGCCTTTTGTCCTTGTGGCGTCGGGCCTCACCTTCTTCCTGCCC
TCGGGTGCCATATGCTTCACCTACTGCAGGATCCTGCTAGCTGCCCGCAAGCAGGCCGTG
CAGGTGGCCTCCCTCACCACCGGCATGGCCAGTCAGGCCTCGGAGACGCTGCAGGTGCCC
AGGACCCCACGCCCAGGGGTGGAGTCTGCTGACAGCAGGCGTCTAGCCACGAAGCACAGC
AGGAAGGCCCTGAAGGCCAGCCTGACGCTGGGCATCCTGCTGGGCATGTTCTTTGTGACC
TGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGC
CTCTTCGATGTCCTCACATGGCTGGGTTACTGTAACAGCACCATGAACCCCATCATCTAC
CCACTCTTCATGCGGGACTTCAAGCGGGCGCTGGGCAGGTTCCTGCCATGTCCACGCTGT
CCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCGCACCTCTCACAGCGGCCCC
CGGCCCGGCCTTAGCCTACAGCAGGTGCTGCCGCTGCCCCTGCCGCCGGACTCAGATTCG
GACTCAGACGCAGGCTCAGGCGGCTCCTCGGGCCTGCGGCTCACGGCCCAGCTGCTGCTT
CCTGGCGAGGCCACCCAGGACCCCCCGCTGCCCACCAGGGCCGCTGCCGCCGTCAATTTC
TTCAACATCGACCCCGCGGAGCCCGAGCTGCGGCCGCATCCACTTGGCATCCCCACGAAC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cilium</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>histamine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of TOR signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P34969" source="Swiss-Prot">
    <name>5-hydroxytryptamine receptor 7</name>
    <general-function>Serotonin receptor activity</general-function>
    <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.</specific-function>
    <gene-name>HTR7</gene-name>
    <locus>10q21-q24</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>84-104
118-138
158-178
202-222
237-257
326-346
368-388</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.97</theoretical-pi>
    <molecular-weight>53554.43</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5302</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HTR7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U68487</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1857143</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>12</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>12</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P34969</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>5HT7R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>5-HT-7</synonym>
      <synonym>5-HT-X</synonym>
      <synonym>Serotonin receptor 7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001296|5-hydroxytryptamine receptor 7
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTW
DAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLI
VSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDR
YLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYT
IYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE
ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSC
IPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK
LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010453|5-hydroxytryptamine receptor 7 (HTR7)
ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTT
CTGCCAGAAGTGGGGCGCGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTC
GCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG
GACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAG
AAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGC
CTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC
GTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTC
ACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAATGTCTTCATCGCC
ATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG
TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG
AAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA
TGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG
ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC
CAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA
GTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA
GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG
CGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG
CTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC
ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC
CCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG
TGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG
CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCTACAAAATGCTGACTACTGTAGAAAA
AAAGGTCATGATTCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serotonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood circulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0004863</id>
      <name>Alpha-1 adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35348" source="Swiss-Prot">
    <name>Alpha-1A adrenergic receptor</name>
    <general-function>Protein heterodimerization activity</general-function>
    <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
    <gene-name>ADRA1A</gene-name>
    <locus>8p21-p11.2</locus>
    <cellular-location>Nucleus membrane</cellular-location>
    <transmembrane-regions>28-51
65-88
100-122
144-167
182-205
274-297
306-329</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.23</theoretical-pi>
    <molecular-weight>51486.005</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:277</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D25235</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>433201</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>22</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>22</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35348</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA1A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA1C</synonym>
      <synonym>Alpha-1A adrenoceptor</synonym>
      <synonym>Alpha-1A adrenoreceptor</synonym>
      <synonym>Alpha-1C adrenergic receptor</synonym>
      <synonym>Alpha-adrenergic receptor 1c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001000|Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A)
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha1-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase C signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, GABAergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium ion transport into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of Rho protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cardiac muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of action potential</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hormone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P35368" source="Swiss-Prot">
    <name>Alpha-1B adrenergic receptor</name>
    <general-function>Protein heterodimerization activity</general-function>
    <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
    <gene-name>ADRA1B</gene-name>
    <locus>5q23-q32</locus>
    <cellular-location>Nucleus membrane</cellular-location>
    <transmembrane-regions>46-70
84-105
116-141
162-184
202-224
296-319
327-351</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.79</theoretical-pi>
    <molecular-weight>56835.375</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:278</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA1B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M99589</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>23</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>23</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35368</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA1B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Alpha-1B adrenoceptor</synonym>
      <synonym>Alpha-1B adrenoreceptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010399|Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010400|Alpha-1B adrenergic receptor (ADRA1B)
ATGAATCCCGACCTGGACACCGGCCACAACACATCAGCACCTGCCCACTGGGGAGAGTTG
AAAAATGCCAACTTCACTGGCCCCAACCAGACCTCGAGCAACTCCACACTGCCCCAGCTG
GACATCACCAGGGCCATCTCTGTGGGCCTGGTGCTGGGCGCCTTCATCCTCTTTGCCATC
GTGGGCAACATCCTAGTCATCTTGTCTGTGGCCTGCAACCGGCACCTGCGGACGCCCACC
AACTACTTCATTGTCAACCTGGCCATGGCCGACCTGCTGTTGAGCTTCACCGTCCTGCCC
TTCTCAGCGGCCCTAGAGGTGCTCGGCTACTGGGTGCTGGGGCGGATCTTCTGTGACATC
TGGGCAGCCGTGGATGTCCTGTGCTGCACAGCGTCCATTCTGAGCCTGTGCGCCATCTCC
ATCGATCGCTACATCGGGGTGCGCTACTCTCTGCAGTATCCCACGCTGGTCACCCGGAGG
AAGGCCATCTTGGCGCTGCTCAGTGTCTGGGTCTTGTCCACCGTCATCTCCATCGGGCCT
CTCCTTGGGTGGAAGGAGCCGGCACCCAACGATGACAAGGAGTGCGGGGTCACCGAAGAA
CCCTTCTATGCCCTCTTCTCCTCTCTGGGCTCCTTCTACATCCCTCTGGCGGTCATTCTA
GTCATGTACTGCCGTGTCTATATAGTGGCCAAGAGAACCACCAAGAACCTAGAGGCAGGA
GTCATGAAGGAGATGTCCAACTCCAAGGAGCTGACCCTGAGGATCCATTCCAAGAACTTT
CACGAGGACACCCTTAGCAGTACCAAGGCCAAGGGCCACAACCCCAGGAGTTCCATAGCT
GTCAAACTTTTTAAGTTCTCCAGGGAAAAGAAAGCAGCTAAGACGTTGGGCATTGTGGTC
GGTATGTTCATCTTGTGCTGGCTACCCTTCTTCATCGCTCTACCGCTTGGCTCCTTGTTC
TCCACCCTGAAGCCCCCCGACGCCGTGTTCAAGGTGGTGTTCTGGCTGGGCTACTTCAAC
AGCTGCCTCAACCCCATCATCTACCCATGCTCCAGCAAGGAGTTCAAGCGCGCTTTCGTG
CGCATCCTCGGGTGCCAGTGCCGCGGCCGCGGCCGCCGCCGACGCCGCCGCCGCCGTCGC
CTGGGCGGCTGCGCCTACACCTACCGGCCGTGGACGCGCGGCGGCTCGCTGGAGCGCTCG
CAGTCGCGCAAGGACTCGCTGGACGACAGCGGCAGCTGCCTGAGCGGCAGCCAGCGGACC
CTGCCCTCGGCCTCGCCGAGCCCGGGCTACCTGGGCCGCGGCGCGCCACCGCCAGTCGAG
CTGTGCGCCTTCCCCGAGTGGAAGGCGCCCGGCGCCCTCCTGAGCCTGCCCGCGCCTGAG
CCCCCCGGCCGCCGCGGCCGCCACGACTCGGGCCCGCTCTTCACCTTCAAGCTCCTGACC
GAGCCCGAGAGCCCCGGGACCGACGGCGGCGCCAGCAACGGAGGCTGCGAGGCCGCGGCC
GACGTGGCCAACGGGCAGCCGGGCTTCAAAAGCAACATGCCCCTGGCGCCCGGGCAGTTT
TAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha1-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>locomotory behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>behavioral response to cocaine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to amphetamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood vessel remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adult heart development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of glycogen catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycogen catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cardiac muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P25100" source="Swiss-Prot">
    <name>Alpha-1D adrenergic receptor</name>
    <general-function>Alpha1-adrenergic receptor activity</general-function>
    <specific-function>This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.</specific-function>
    <gene-name>ADRA1D</gene-name>
    <locus>20p13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>96-121
134-159
170-192
214-238
252-275
349-373
381-405</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.44</theoretical-pi>
    <molecular-weight>60462.205</molecular-weight>
    <chromosome-location>20</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:280</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA1D</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M76446</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>177807</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>24</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>24</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P25100</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA1D_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA1A</synonym>
      <synonym>Alpha-1A adrenergic receptor</synonym>
      <synonym>Alpha-1D adrenoceptor</synonym>
      <synonym>Alpha-1D adrenoreceptor</synonym>
      <synonym>Alpha-adrenergic receptor 1a</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019001|Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019002|Alpha-1D adrenergic receptor (ADRA1D)
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCGGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha1-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of the force of heart contraction involved in baroreceptor response to increased systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>DNA metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0004864</id>
      <name>Alpha-2 adrenergic receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08913" source="Swiss-Prot">
    <name>Alpha-2A adrenergic receptor</name>
    <general-function>Thioesterase binding</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline &gt; clonidine &gt; epinephrine &gt; norepinephrine &gt; phenylephrine &gt; dopamine &gt; p-synephrine &gt; p-tyramine &gt; serotonin = p-octopamine. For antagonists, the rank order is yohimbine &gt; phentolamine = mianserine &gt; chlorpromazine = spiperone = prazosin &gt; propanolol &gt; alprenolol = pindolol.</specific-function>
    <gene-name>ADRA2A</gene-name>
    <locus>10q24-q26</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>34-59
71-96
107-129
152-172
195-217
375-395
410-429</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>10.2</theoretical-pi>
    <molecular-weight>48956.275</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:281</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M23533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178196</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>25</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>25</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08913</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2R</synonym>
      <synonym>ADRAR</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C10</synonym>
      <synonym>Alpha-2A adrenoceptor</synonym>
      <synonym>Alpha-2A adrenoreceptor</synonym>
      <synonym>Alpha-2AAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021255|Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC
ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG
CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG
GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC
GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG
TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC
GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC
ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC
TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG
CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC
TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT
CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC
ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG
GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG
CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT
CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG
GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG
GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG
CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG
TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC
ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC
TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC
AGGAAGCGGATCGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heterotrimeric G-protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>norepinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thioesterase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-1B adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-2C adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of uterine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female pregnancy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transmembrane transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fear response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion-dependent exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intestinal absorption</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasodilation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of membrane protein ectodomain proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>thermoception</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of lipid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Rho protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hormone stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of potassium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P18089" source="Swiss-Prot">
    <name>Alpha-2B adrenergic receptor</name>
    <general-function>Epinephrine binding</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine &gt; norepinephrine &gt; epinephrine = oxymetazoline &gt; dopamine &gt; p-tyramine = phenylephrine &gt; serotonin &gt; p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine &gt; chlorpromazine &gt; phentolamine &gt; mianserine &gt; spiperone &gt; prazosin &gt; alprenolol &gt; propanolol &gt; pindolol.</specific-function>
    <gene-name>ADRA2B</gene-name>
    <locus>2p13-q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>13-38
49-69
87-107
129-149
173-193
370-393
403-423</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.52</theoretical-pi>
    <molecular-weight>49565.8</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:282</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M34041</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178198</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>26</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>26</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P18089</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2L1</synonym>
      <synonym>ADRA2RL1</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C2</synonym>
      <synonym>Alpha-2B adrenoceptor</synonym>
      <synonym>Alpha-2B adrenoreceptor</synonym>
      <synonym>Alpha-2BAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010396|Alpha-2B adrenergic receptor
MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL
VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY
NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS
FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV
ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE
EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL
TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP
VIYTIFNQDFRRAFRRILCRPWTQTAW</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B)
ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC
TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC
CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG
GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC
CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC
GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC
AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC
GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG
CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT
TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA
CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG
CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG
GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG
ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA
GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG
GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC
TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT
GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG
GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT
GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC
TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA
CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC
CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smooth muscle contraction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <polypeptide id="P18825" source="Swiss-Prot">
    <name>Alpha-2C adrenergic receptor</name>
    <general-function>Protein homodimerization activity</general-function>
    <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.</specific-function>
    <gene-name>ADRA2C</gene-name>
    <locus>4p16</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>52-76
89-114
125-147
169-191
208-231
380-407
421-441</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>10.69</theoretical-pi>
    <molecular-weight>49521.585</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:283</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ADRA2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03853</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>178194</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>27</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>27</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P18825</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ADA2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADRA2L2</synonym>
      <synonym>ADRA2RL2</synonym>
      <synonym>Alpha-2 adrenergic receptor subtype C4</synonym>
      <synonym>Alpha-2C adrenoceptor</synonym>
      <synonym>Alpha-2C adrenoreceptor</synonym>
      <synonym>Alpha-2CAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000681|Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C)
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC
GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG
TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG
CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG
CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG
CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC
ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC
AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG
TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC
AGGCAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon terminus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha-2A adrenergic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epinephrine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>alpha2-adrenergic receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female pregnancy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of uterine smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0000442</id>
      <name>Histamine H1 receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11520476</pubmed-id>
            <citation>Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35367" source="Swiss-Prot">
    <name>Histamine H1 receptor</name>
    <general-function>Histamine receptor activity</general-function>
    <specific-function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.</specific-function>
    <gene-name>HRH1</gene-name>
    <locus>3p25</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>30-52
63-83
102-123
144-164
190-210
417-438
451-470</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.58</theoretical-pi>
    <molecular-weight>55783.61</molecular-weight>
    <chromosome-location>3</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5182</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HRH1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z34897</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>510296</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35367</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>HRH1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>H1R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016092|Histamine H1 receptor
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016093|Histamine H1 receptor (HRH1)
ATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC
ACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC
ACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT
GTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC
ATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC
CTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC
CTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC
AAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT
CCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT
GAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC
CTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC
TGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG
CCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG
AAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC
AAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC
TACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC
TATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA
CATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA
ACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT
AACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG
TATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC
ATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC
TGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC
TCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG
AGAATTCTGCATATTCGCTCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>histamine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>histamine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>eosinophil chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of chemical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inositol phosphate-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>modulation of synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>visual learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inositol trisphosphate biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to histamine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vascular permeability</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
